



Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758

Yoshiko Kagoshima^a, Makoto Mori^b, Eiko Suzuki^c, Takahiro Shibayama^c, Tamako Iida^d, Yasuki Kamai^d, Toshiyuki Konosu^{a,*}

^a Medicinal Chemistry Research Laboratories II, Daiichi Sankyo Co., Ltd, 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan

^b Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan

^c Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd, 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan

^d Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd, 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan

ARTICLE INFO

Article history:

Received 13 March 2009

Revised 27 April 2009

Accepted 29 April 2009

Available online 3 May 2009

Keywords:

Antifungal

CS-758

Prodrug

Parenteral formulation

Phosphoryl ester

ABSTRACT

In this study, the synthesis and evaluation of a number of esters of CS-758 as injectable prodrugs are described. Phosphoryl ester **1a** was soluble in water (>30 mg/mL) and was converted to CS-758 in human liver microsome. It was also converted to CS-758 in rats after iv administration, wherein the bioavailability of CS-758 was 53%. Compound **1a** (iv) reduced the viable cell counts in kidneys in a murine systemic *Candida albicans* infection model, wherein the effect was comparable to or slightly superior to that of CS-758 (po). The prodrug **1a** proved to be a promising injectable antifungal agent whose further evaluation is warranted.

© 2009 Elsevier Ltd. All rights reserved.

There is a great medical need for an injectable antifungal agent with a broad spectrum for the treatment of severe deep mycoses of hospitalized patients. Currently, fluconazole (or fosfluconazole) and amphotericin B are available for parenteral use, but they have limitations in terms of antifungal spectra and safety, respectively.¹ Most of the azoles under development have a broader spectrum but cannot be administered parenterally without modification because of low water-solubility.^{2,3} There have been some efforts to overcome this problem by using a prodrug approach.⁴

Previously, we identified CS-758⁵ (Fig. 1), which has a broad antifungal spectrum covering *Aspergillus* spp., fluconazole-resistant *Candida* spp. and has a good safety profile including low drug–drug interaction. Since the water solubility of CS-758 was, however, too low for parenteral formulation, we conducted a study on a new prodrug of CS-758, which should have sufficient water-solubility and efficient bioconversion.

CS-758 has two obvious functional groups, namely the tertiary hydroxy and the triazole groups, with the possibility of being linked to a pro-moiety. It is known that water-soluble prodrugs can be readily accessed by alkylating a triazole ring with halomethyl acetate derivatives to give a quarternary ammonium salt prodrug.^{4d,6} However, the prodrugs in this class

liberate an equivalent amount of formaldehyde or acetaldehyde in vivo when cleaved. Fosfluconazole,^{1d,e} the phosphoric acid ester prodrug of fluconazole, has improved water-solubility, but its antifungal spectrum is limited only to that of fluconazole. Consequently, we focused our efforts on identifying a suitable polar or charged group with which we could functionalize CS-758 on the tertiary hydroxy group. In this paper, we describe the synthesis and the characteristics of such prodrugs of CS-758.

For water-soluble prodrugs, we first planned to prepare compounds **1a–c** in order to check their solubility in water and ability to release CS-758. Then, compounds **2a** and **2b**, derivatives of **1b**, were investigated. Similarly, compounds **3a–c**, derivatives of **1c**, were investigated (Scheme 1–5).






Figure 1. Structural formula of CS-758.


* Corresponding author. Tel.: +81 3 3680 0151; fax: +81 3 5496 8344.




Scheme 1. Synthesis of **1a**. Reagents and conditions: (a) $i\text{-Pr}_2\text{NP}(\text{OAllyl})_2$, 1*H*-tetrazole, CH_2Cl_2 , 89%; (b) $t\text{-BuOOH}$, CH_2Cl_2 , 82%; (c) $\text{PdCl}_2(\text{PPh}_3)_2$, $n\text{-Bu}_3\text{SnH}$, CH_2Cl_2 ; (d) NaHCO_3 aq, then C-18 reverse-phase column chromatography, 45%, two steps.




Scheme 2. Synthesis of **1b**. Reagents and conditions: (a) 1- NaHCO_3 , H_2O , 2-(4-(MeO) BnCl), 60%; (b) allyl chloroformate, DMAP, CH_2Cl_2 , 86%; (c) anisole, TFA, quant.; (d) $(\text{COCl})_2$, cat. DMF, THF, 90%; (e) 1- NaH , THF; (f) **2-10**, 16%; (g) $\text{PdCl}_2(\text{PPh}_3)_2$, $n\text{-Bu}_3\text{SnH}$, CH_2Cl_2 , quant.



Scheme 3. Synthesis of **1c**. Reagents and conditions: (a) $(\text{COCl})_2$, cat. DMF, CH_2Cl_2 ; (b) NaH , **13**, 26%; (c) CH_3NHNH_2 , CH_2Cl_2 , 85%.



Scheme 4. Synthesis of compound **1b**'s derivatives **2a** and **2b**. Reagents and conditions: (a) monoallyl succinic acid chloride, NEt_3 , DMAP, CH_2Cl_2 , 77%; (b) 1- $\text{PdCl}_2(\text{PPh}_3)_2$, $n\text{-Bu}_3\text{SnH}$, CH_2Cl_2 , 2- NaHCO_3 aq, then C-18 reverse phase column, 34%; (c) 1- $i\text{-Pr}_2\text{NP}(\text{OAllyl})_2$, 1*H*-tetrazole, CH_2Cl_2 ; 2- $t\text{-BuOOH}$, CH_2Cl_2 , 84%; (d) $\text{PdCl}_2(\text{PPh}_3)_2$, $n\text{-Bu}_3\text{SnH}$, CH_2Cl_2 then NaHCO_3 aq, 52%, two steps.



Scheme 5. Synthesis of compound **1c**'s derivatives **3a–c**. (a) $(\text{COCl})_2$, cat. DMF, THF; (b) NaH, **18**, THF, 37%; (c) 1-MeOTf, *i*-Pr₂NEt, CH₂Cl₂, 2-DOWEX1 × 4 (Cl form), 32%; (d) $(\text{COCl})_2$, cat. DMF, CH₂Cl₂; (e) NaH, **20**, THF, 10%; (f) MeNHNH₂, CH₂Cl₂, 61%.

Table 1
Solubility in water and conversion to CS-758 (in human plasma and liver microsome)

Compd	Solubility in water (mg/mL)	In vitro (human) ^a			
		Plasma		Liver ms	
		30 min	120 min	30 min	120 min
1a	>30	–	–	+	+
1b	<1	±	±	– ^b	– ^b
2a	>10	–	–	– ^b	– ^b
2b	>10	–	–	– ^b	– ^b
1c	<1	–	±	–	–
3a	<1	–	±	–	–
3b	>10	+	++	–	–
3c	<1	–	–	–	–

^a –; no detection of CS-758 (<10%), ±; low formation of CS-758 (10–30%), +; middle formation of CS-758 (30–60%), ++; high formation of CS-758 (>60%).

^b Compound **1b** was detected.

The synthesis of **1a** is shown in Scheme 1. Despite the steric hindrance of the tertiary hydroxy group of CS-758, compound **1a** could smoothly be synthesized from CS-758 using the phosphorylation procedure developed by Fraser-Reid.⁷ Thus, CS-758 was treated with diallyl diisopropylphosphoramidite in the presence of 1*H*-tetrazole in dichloromethane to afford the diallyl phosphite **4**. Phosphite **4** was then oxidized by *t*-butyl hydroperoxide to give the corresponding phosphate **5**. Removal of the two allyl groups was accomplished by use of bis(triphenylphosphine)dichloropalladium and tri(*n*-butyl)tin hydride in dichloromethane. The sodium salt **1a** was prepared by treatment with sodium hydrogen carbonate and purified by C-18 reverse-phase column chromatography.

The syntheses of **1b** and **1c** are shown in Schemes 2 and 3. The OH group of glycolic acid **6** was protected by the allyloxycarbonyl group in three steps to give **9**. Treatment of **9** with oxalyl chloride in dichloromethane afforded corresponding acid chloride **10**. The usual methods reported for the preparation of esters from alcohols were not successful with CS-758 because of its steric hindrance. After many attempts to esterify this hydroxyl moiety, a direct esterification reaction of oxide anion, which was generated from CS-758 and NaH in THF, with acid chloride **10** at room




Figure 2. Conversion of **1a** (○) to CS-758 (●) in human liver microsome.

temperature, provided a modest yield (8–10%) of the desired ester **11**. The allyloxycarbonyl group of **11** was removed by bis(triphenylphosphine)dichloropalladium and tri(*n*-butyl)hydride to give compound **1b**.

In a similar manner, **1c** was synthesized from CS-758 and acid chloride **13** which was prepared from *N*-phthaloyl glycine **12**.




Figure 3. Conversion of **3b** (○) to CS-758 (●) in human plasma.




Figure 4. Plasma level of CS-758 after iv administration of **1a** to rats at a dose of 2 mg/kg (average of three rats).




Figure 5. Plasma level of CS-758 after iv administration of **3b** to rats at a dose of 2 mg/kg (average of three rats).

Removal of the phthaloyl group in **14** was achieved by the use of methylhydrazine to afford the desired amine **1c**.

The syntheses of **2a** and **2b** are shown in Scheme 4. We attempted to modify the hydroxy group of **1b** with a hydrophilic function such as succinic acid or phosphoric acid groups. **1b** was allowed to react with mono allyl succinic acid chloride in dichloromethane to give allyl ester **15**. The allyl group in **15** was removed by the use of Pd(0) and tri(*n*-butyl)tin hydride. The sodium salt **2a** was prepared by treatment with sodium hydrogen carbonate and purified by C-18 reverse-phase column chromatography.

When compound **1b** was treated with diallyl diisopropylphosphoramidite in the presence of 1*H*-tetrazole in dichloromethane, a

smooth conversion to the diallyl phosphite was achieved. This phosphite was oxidized successively with *t*-butyl hydroperoxide to give the corresponding phosphate **16**. Removal of the allyl groups was accomplished by use of bis(triphenylphosphine)dichloropalladium and tri(*n*-butyl)tin hydride in dichloromethane to afford **1c**.

The syntheses of **3a–c** are shown in Scheme 5. *N,N*-Dimethylalaninoglycine ester **3a** was synthesized from CS-758 and **18**. **3a** was allowed to react with methyl trifluoromethanesulfonate in CH₂Cl₂ followed by anion exchange chromatography with DOWEX-1 to afford quaternary ammonium compound **3b**. β-Alanine ester **3c** was synthesized in a similar manner to that shown in Scheme 3.

The solubility in water and the conversion rate to CS-758 in human plasma and in human liver microsome (ms) are shown in Table 1. Compound **1a** has good water solubility (>30 mg/mL). **1a** was converted to CS-758 in human liver ms, but it was not converted to CS-758 in human plasma. The solubility of **1b** and **1c** was not sufficient. Though these compounds were not converted to CS-758 in human liver ms, they released CS-758 in human plasma moderately. Compounds **2a** and **2b** were sufficiently improved in water-solubility. These compounds were not converted to CS-758 in human plasma. When **2a** and **2b** were incubated with human liver ms, they were smoothly converted to intermediate **1b**. However, **1b** was not converted to CS-758 in human liver ms. Compounds **3a** and **3c** did not show any improvement in either water-solubility or conversion rates to CS-758, unfortunately. However, betaine ester **3b** has good water solubility. Furthermore, compound **3b** was quickly converted to CS-758 in human plasma.

The disappearance of **1a** and the formation of CS-758 after incubation of **1a** with human liver ms are shown in Figure 2, and the disappearance of **3b** and formation of CS-758 after incubation of **3b** with human plasma are shown in Figure 3.

The in vivo conversion of **1a** and **3b** to CS-758 upon iv administration to rats is shown in Figures 4 and 5, respectively. When **1a** was administrated to rats, CS-758 was gently formed and slowly eliminated with *t*_{1/2} of 5.7 h. The bioavailability⁸ of CS-758 was 53%. When **3b** was administrated to rats, CS-758 was quickly formed and a high concentration of CS-758 was observed (*C*_{max}, 1.3 µg/mL). But CS-758 was quickly eliminated and the bioavailability of CS-758 was only 3.3%. The reason for the low conversion rate of **3b** was unclear.

The in vivo efficacies of CS-758 (oral administration) and prodrug **1a** (iv administration) were evaluated in a systemic *C. albicans* infection model in mice (Fig. 6). The efficacy of iv-administered prodrug **1a** was comparable or slightly superior to the efficacy of orally administered CS-758.

Consequently, the phosphoryl ester prodrug **1a** proved to be a promising agent as an antifungal agent for parenteral use and its further preclinical evaluation is warranted.




Figure 6. In vivo efficacy of compound **1a** (iv) against murine intravenous infection with *C. albicans* SANK 51486 compared with that of CS-758 (po).

References and notes

- (a) Maesaki, S.; Kohno, S. *Saishin Igaku* **1992**, *47*, 277; (b) Saxena, S.; Khan, J. A.; Ghosh, P. C. *J. Antimicrob. Chemother.* **1998**, *42*, 635; (c) Petit, C.; Cheron, M.; Joly, V.; Rodrigues, J. M.; Bolard, J.; Gaboriau, F. *J. Antimicrob. Chemother.* **1998**, *42*, 779; (d) Bentley, A.; Butters, M.; Green, S. P.; Learmonth, W. J.; MacRae, J. A.; Morland, M. C.; O'Connor, G.; Skuse, J. *Org. Process Res. Dev.* **2002**, *6*, 109; (e) Kawakami, Y.; Nagino, K.; Shinkai, K.; Sobue, S.; Abe, M.; Ishiko, J. *Nippon Yakurigaku Zasshi* **2004**, *124*, 41.
- (a) Fung-Tomc, J. C.; White, T. C.; Minassian, B.; Huczko, E.; Bonner, D. P. *Diagn. Microbiol. Infect. Dis.* **1999**, *35*, 163; (b) Kitazaki, T.; Ichikawa, T.; Tasaka, A.; Hosono, H.; Matsushita, Y.; Hayashi, R.; Okonogi, K.; Itoh, K. *Chem. Pharm. Bull.* **2000**, *48*, 1935; (c) Van Cutsem J. *Mycoses* **1989**, *32*, 14.
- Voriconazole can be administered by infusion by complexation technology using sodium salt of sulfobutyl ether β -cyclodextrin (a) Abel, S.; Allan, R.; Gandelman, K.; Tomaszewski, K.; Webb, D. J.; Wood, N. D. *Clin. Drug Invest.* **2008**, *28*, 409; (b) Harding, V. D. WO 98/58677, 1998; *Chem. Abstr.* **1999**, *130*, 51789.
- (a) Ohwada, J.; Murasaki, C.; Yamazaki, T.; Ichihara, S.; Umeda, I.; Shimma, N. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2775; (b) Ichikawa, T.; Kitazaki, T.; Matsushita, Y.; Yamada, M.; Hayashi, R.; Yamaguchi, M.; Kiyota, Y.; Okonogi, K.; Itoh, K. *Chem. Pharm. Bull.* **2001**, *49*, 1102; (c) Ueda, Y.; Matiskella, J. D.; Golik, J.; Connolly, T. P.; Hudyma, T. W.; Venkatesh, S.; Dali, M.; Kang, S.-H.; Barbour, N.; Tejwani, R.; Varia, S.; Knipe, J.; Zheng, M.; Mathew, M.; Mosure, K.; Clark, J.; Lamb, L.; Medin, I.; Gao, Q.; Huang, S.; Chena, C.-P.; Bronson, J. J. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3669; (d) Ohwada, J.; Tsukazaki, M.; Hayase, T.; Oikawa, N.; Isshiki, Y.; Fukuda, H.; Mizuguchi, E.; Sakaitani, M.; Shiratori, Y.; Yamazaki, T.; Ichihara, S.; Umeda, I.; Shimma, N. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 191.
- (a) Oida, S.; Tajima, Y.; Konosu, T.; Nakamura, Y.; Somada, A.; Tanaka, T.; Habuki, S.; Harasaki, T.; Kamai, Y.; Fukuoka, T.; Ohya, S.; Yasuda, H. *Chem. Pharm. Bull.* **2000**, *48*, 694; (b) Konosu, T.; Oida, S.; Nakamura, Y.; Seki, S.; Uchida, T.; Somada, A.; Mori, M.; Harada, Y.; Kamai, Y.; Harasaki, T.; Fukuoka, T.; Ohya, S.; Yasuda, H.; Shibayama, T.; Inoue, S.; Nakagawa, A.; Seta, Y. *Chem. Pharm. Bull.* **2001**, *49*, 1647; (c) Kamai, Y.; Harasaki, T.; Fukuoka, T.; Ohya, S.; Uchida, K.; Yamaguchi, H.; Kuwahara, S. *Antimicrob. Agents Chemother.* **2002**, *46*, 367.
- Davidsen, S. K.; Summers, J. B.; Albert, D. H.; Holms, J. H.; Heyman, H. R.; Magoc, T. J.; Conway, R. G.; Rhein, D. A.; Carter, G. W. *J. Med. Chem.* **1994**, *37*, 4423.
- Fraser-Reid, B.; Yu, K.-L. *Tetrahedron Lett.* **1988**, *29*, 979.
- Bioavailability (BA) was calculated by the following. BA (%) = [(AUC of CS-758 after iv administration of the prodrug)/(AUC of CS-758 after iv administration of CS-758 dissolved in polyethylene glycol solution)] $\times$ 100.